TY - JOUR
T1 - Risk of severe erectile dysfunction in primary hyperaldosteronism
T2 - A population-based propensity score matching cohort study
AU - Chang, Chia Hui
AU - Chueh, Shih Chieh J.
AU - Wu, Vin Cent
AU - Chen, Likwang
AU - Lin, Yen Hung
AU - Hu, Ya Hui
AU - Wu, Kwan Dun
AU - Tsai, Yao Chou
N1 - Funding Information:
The study is in part based on data provided by Bureau of National Health Insurance, Department of Health, Taiwan. We also express our sincere gratitude to all staff of the Taiwan Clinical Trial Consortium. We thank Mr. Eric B Chueh of Case Western Reserve University, Cleveland, OH, for English editing., Supported by the National Science Council, National Taiwan University Hospital, and National Health Research Institutes, Taiwan. This work was also supported by the Ministry of Science and Technology (MOST) of the Republic of China (Taiwan) (grant MOST 106-2321-B-182-002).
Funding Information:
Supported by the National Science Council, National Taiwan University Hospital, and National Health Research Institutes, Taiwan. This work was also supported by the Ministry of Science and Technology (MOST) of the Republic of China (Taiwan) (grant MOST 106-2321-B-182-002).
Publisher Copyright:
© 2018
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/3
Y1 - 2019/3
N2 - Background: An elevated plasma aldosterone level has been reported as an independent risk factor for severe erectile dysfunction in men. The aim of this study was to explore whether primary hyperaldosteronism patients experience erectile dysfunction after targeted treatment. Methods: We conducted a population-based cohort study of men with newly identified primary hyperaldosteronism/aldosterone-producing adenoma from January 1, 1997, to December 31, 2009. Men with essential hypertension and normotension were matched to the primary hyperaldosteronism group according to propensity score matching. Results: We identified 1,067 men with primary hyperaldosteronism (mean age, 46.7 ± 12.8 years) and matched them with the same number of men with essential hypertension or normotension. During the mean follow-up interval of 5.4 years, the incident rates of total erectile dysfunction were 5.7, 3.9, and 3.1 per 1,000 person-years for the primary hyperaldosteronism, essential hypertension, and normotension groups, respectively. Men with primary hyperaldosteronism exhibited a higher risk of erectile dysfunction compared with men with normotension (competing risks hazard ratio, 1.83), and no difference was seen in comparison with men who have essential hypertension. After adrenalectomy, men who have primary hyperaldosteronism had a higher risk of exhibiting severe erectile dysfunction compared with men who have essential hypertension (competing risks hazard ratio, 2.44) or normotension (competing risks hazard ratio, 2.90). Conclusion: Men with primary hyperaldosteronism reported a higher incidence of severe erectile dysfunction than normotension controls despite targeted treatment. The risk of severe erectile dysfunction increased after men who have primary hyperaldosteronism underwent adrenalectomy. This result raises the possibility of severe erectile dysfunction after adrenalectomy and calls for a prospective large-scale study of men who have aldosterone-producing adenoma regarding their erectile function both before and after adrenalectomy.
AB - Background: An elevated plasma aldosterone level has been reported as an independent risk factor for severe erectile dysfunction in men. The aim of this study was to explore whether primary hyperaldosteronism patients experience erectile dysfunction after targeted treatment. Methods: We conducted a population-based cohort study of men with newly identified primary hyperaldosteronism/aldosterone-producing adenoma from January 1, 1997, to December 31, 2009. Men with essential hypertension and normotension were matched to the primary hyperaldosteronism group according to propensity score matching. Results: We identified 1,067 men with primary hyperaldosteronism (mean age, 46.7 ± 12.8 years) and matched them with the same number of men with essential hypertension or normotension. During the mean follow-up interval of 5.4 years, the incident rates of total erectile dysfunction were 5.7, 3.9, and 3.1 per 1,000 person-years for the primary hyperaldosteronism, essential hypertension, and normotension groups, respectively. Men with primary hyperaldosteronism exhibited a higher risk of erectile dysfunction compared with men with normotension (competing risks hazard ratio, 1.83), and no difference was seen in comparison with men who have essential hypertension. After adrenalectomy, men who have primary hyperaldosteronism had a higher risk of exhibiting severe erectile dysfunction compared with men who have essential hypertension (competing risks hazard ratio, 2.44) or normotension (competing risks hazard ratio, 2.90). Conclusion: Men with primary hyperaldosteronism reported a higher incidence of severe erectile dysfunction than normotension controls despite targeted treatment. The risk of severe erectile dysfunction increased after men who have primary hyperaldosteronism underwent adrenalectomy. This result raises the possibility of severe erectile dysfunction after adrenalectomy and calls for a prospective large-scale study of men who have aldosterone-producing adenoma regarding their erectile function both before and after adrenalectomy.
UR - http://www.scopus.com/inward/record.url?scp=85056998162&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056998162&partnerID=8YFLogxK
U2 - 10.1016/j.surg.2018.08.020
DO - 10.1016/j.surg.2018.08.020
M3 - Article
C2 - 30473204
AN - SCOPUS:85056998162
VL - 165
SP - 622
EP - 628
JO - Surgery
JF - Surgery
SN - 0039-6060
IS - 3
ER -